1. Achieving and Maintaining Weight Loss in Obesity: Clinical Evidence for Novel Approaches

3. Mean BMI Around the Globe in Men 18 and Over: 2014

4. The Risk for Comorbid Disease With Increasing BMI

5. Weight Loss, Metabolic, and Other Health Benefits

6. Mechanisms Involved in the Development of T2DM

7. The Link Between the Gut, Brain, Adipose Tissue, and Body Weight

8. Interventions for Weight Loss in the Overweight and Obese

9. Barriers and Complications to Obesity Management

10. EMA Approved Treatments for Weight Management Prior to 2015

11. Orlistat Reversibly Inhibits Lipases in the GI Tract

12. XENDOS: Effect of Long-term Treatment With Orlistat on Body Weight

13. Mean Changes in Coronary Heart Disease Risk Factors With Orlistat

14. Reported Adverse Effects With Orlistat Use

15. Naltrexone SR /Bupropion SR MOA to Initiate and Sustain Weight Loss

16. Effect of Naltrexone SR/Bupropion SR on Body Weight Across Multiple Trials

17. Naltrexone SR/Bupropion SR: Most Common Treatment-Emergent AEs

18. GLP-1 Secretion in the Gut and Appetite Regulation

19. Liraglutide Approval for Weight Management

20. SCALE Obesity and Prediabetes: Effect of Liraglutide on Weight at 56 Weeks

21. Liraglutide: TEAEs Reported in Phase 3 Trials

22. Liraglutide vs Orlistat For Weight Loss in Patients Without Diabetes Who Are Obese

23. Guidelines Recommendations for the Management of Obese Patients

24. Practical Weight-loss Objectives in Patients With Obesity

25. Abbreviations

26. Abbreviations (cont)

27. Abbreviations (cont)